Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
Georgina V. Long(Royal North Shore Hospital), Keith T. Flaherty(Massachusetts General Hospital), Daniil Stroyakovskiy(Moscow City Oncology Hospital №62), Helen Gogas(Laiko General Hospital of Athens), E. Levchenko(Institute of Oncology NN Petrov), Filippo de Braud(Fondazione IRCCS Istituto Nazionale dei Tumori), James Larkin(Royal Marsden NHS Foundation Trust), Claus Garbe(University of Tübingen), Thomas Jouary, Axel Hauschild(University Hospital Schleswig-Holstein), Vanna Chiarion‐Sileni(Istituto Oncologico Veneto), Célèste Lebbé(Assistance Publique – Hôpitaux de Paris), Mario Mandalà(Ospedale Papa Giovanni XXIII), Michael Millward(Sir Charles Gairdner Hospital), Ana Arance(Hospital Clínic de Barcelona), Igor Bondarenko(Dnipro State Medical University), John B.A.G. Haanen(The Netherlands Cancer Institute), Johan Hansson(Karolinska Institutet), Jochen Utikal(University Hospital Heidelberg), Virginia Ferraresi(National Cancer Institute), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Volodymr Probachai, Dirk Schadendorf(Essen University Hospital), Paul Nathan(Mount Vernon Cancer Centre), Caroline Robert(Université Paris-Sud), Antoni Ribas(UCLA Jonsson Comprehensive Cancer Center), M. A. Davies(The University of Texas MD Anderson Cancer Center), Stephen Lane(Novartis (United States)), Jeffery J. Legos(Novartis (United States)), Bijoyesh Mookerjee(Novartis (United States)), Jean‐Jacques Grob(Aix-Marseille Université)
Cited by 649Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis